: Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease | wallstreet:online
Links shared publicly online about this topic.
- 776total visits
: Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease | wallstreet:online
GENEVA, October 25, 2010 /PRNewswire/ - Study Met its Primary Endpoint - Risk of Converting to Multiple Sclerosis (McDonald Criteria) Was Reduced by Half in Patients Treated With Rebif(R) 44 mcg Three Times a Week Merck Serono, a division of ...
View full resource at wallstreet-online.de
Tags: Multiple Sclerosis, Disease and Condition, Merck & Co., disease
Most Recently Shared on October 25, 2010 at 1:38 pm By:
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First ...... http://bit.ly/bV9uRH
Advertisement
